as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹608.95
Change
+14.85 (2.5%)
Open
₹597.95
Prev. Close
₹594.1
Day High
₹621.95
Day Low
₹597.35
Volume Analysis
Traded
2,095,862
Delivered
480,889
Delivery %
22.94%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Trading within 3% of its 52-week high (₹616.0)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year revenue growth (15.0%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹646.09 | ₹634.02 | ₹621.49 | ₹609.42 | ₹596.89 | ₹584.82 | ₹572.29 |
| Fibonacci | ₹634.02 | ₹624.62 | ₹618.82 | ₹609.42 | ₹600.02 | ₹594.22 | ₹584.82 |
| Camarilla | ₹615.72 | ₹613.46 | ₹611.21 | ₹609.42 | ₹606.7 | ₹604.44 | ₹602.19 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+17.09%
1 Week
+2.18%
1 Month
+5.18%
3 Months
+15.9%
6 Months
+31.08%
1 Year
+5.83%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹220.68
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
11.75%
Net margin 10.52% × asset turnover 0.76x × equity multiplier 1.47x
Company Overview
Sector
Healthcare
Market Cap
₹14,319 Cr
P/E (TTM)
34.4
ROE
14.4%
Book Value
₹130.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Indegene Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (100/100), while Valuation (36/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹616.0). Strong 3-year revenue growth (15.0%).
TopFund Score — Fundamentals Quality
69/100 — GoodData confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company is expected to give good quarter
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Indegene hosted Digital Summit 2026 on Sept. 22 and VITAL Awards recognizing life sciences leaders.
Indegene subsidiaries merged in Germany effective 9 September 2026; entity renamed Indegene Healthcare Germany GmbH.
US court preliminarily approved Indegene Inc.’s class-action settlement; final hearing set for 12 January 2027, max USD 4.72 million.
Indegene schedules investor meetings with MFS, ASK, Mirae on 24 Aug 2026; Goldman Sachs and Seven Canyon on 25 Aug 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 608 | 636 | 673 | 673 | 676 | 687 | 720 | 756 | 761 | 804 | 942 | 1,003 | 1,063 |
| Expenses + | 511 | 515 | 524 | 534 | 548 | 561 | 589 | 608 | 606 | 664 | 783 | 840 | 889 |
| Operating Profit | 97 | 121 | 149 | 139 | 129 | 126 | 132 | 148 | 155 | 141 | 160 | 164 | 174 |
| OPM % | 16.0% | 19.0% | 22.0% | 21.0% | 19.0% | 18.0% | 18.0% | 20.0% | 20.0% | 17.0% | 17.0% | 16.0% | 16.0% |
| Other Income + | 28 | 12 | 13 | 26 | 22 | 21 | 38 | 26 | 22 | 20 | 19 | -10 | 29 |
| Interest | 13 | 12 | 12 | 12 | 12 | 4 | 3 | 3 | 4 | 4 | 5 | 7 | 6 |
| Depreciation | 20 | 20 | 18 | 18 | 20 | 19 | 20 | 21 | 22 | 23 | 40 | 42 | 44 |
| Profit before tax | 92 | 101 | 132 | 134 | 120 | 124 | 146 | 149 | 152 | 133 | 135 | 105 | 153 |
| Tax % | 26.0% | 25.0% | 25.0% | 29.0% | 27.0% | 26.0% | 25.0% | 21.0% | 23.0% | 23.0% | 24.0% | 24.0% | 24.0% |
| Net Profit + | 68 | 75 | 99 | 95 | 88 | 92 | 110 | 118 | 116 | 102 | 103 | 80 | 116 |
| EPS in Rs | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 4 | 4 | 3 | 5 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 553 | 643 | 966 | 1,665 | 2,306 | 2,590 | 2,839 | 3,510 | 3,813 |
| Expenses + | 511 | 499 | 736 | 1,378 | 1,910 | 2,084 | 2,292 | 2,892 | 3,175 |
| Operating Profit | 42 | 144 | 230 | 287 | 396 | 505 | 548 | 619 | 638 |
| OPM % | 8.0% | 22.0% | 24.0% | 17.0% | 17.0% | 20.0% | 19.0% | 18.0% | 17.0% |
| Other Income + | 7 | -102 | -3 | -21 | 58 | 79 | 94 | 52 | 59 |
| Interest | 6 | 9 | 7 | 6 | 31 | 49 | 22 | 19 | 22 |
| Depreciation | 17 | 19 | 26 | 33 | 60 | 76 | 80 | 126 | 149 |
| Profit before tax | 26 | 14 | 195 | 226 | 363 | 459 | 539 | 525 | 526 |
| Tax % | 45.0% | 191.0% | 23.0% | 28.0% | 27.0% | 27.0% | 25.0% | 24.0% | — |
| Net Profit + | 14 | -12 | 149 | 163 | 266 | 337 | 407 | 401 | 401 |
| EPS in Rs | 90 | -40 | 952 | 938 | 12 | 15 | 17 | 17 | 17 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 12.0% | 13.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Reserves | 73 | -105 | 324 | 764 | 1,020 | 1,385 | 2,568 | 3,091 |
| Borrowings + | 147 | 483 | 51 | 66 | 502 | 490 | 102 | 144 |
| Other Liabilities + | 108 | 222 | 220 | 524 | 638 | 627 | 609 | 1,337 |
| Total Liabilities | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 | 4,620 |
| Fixed Assets + | 104 | 119 | 86 | 138 | 664 | 646 | 678 | 1,812 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 12 |
| Investments | 0 | 13 | 0 | 120 | 614 | 796 | 1,290 | 1,100 |
| Other Assets + | 225 | 468 | 510 | 1,096 | 926 | 1,103 | 1,355 | 1,697 |
| Total Assets | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 | 4,620 |
| Equity Capital | 0 | 0 | 0 | 0 | 44 | 44 | 48 | 48 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 65 | 22 | 172 | 297 | 130 | 508 | 442 | 651 |
| Cash from Investing Activity + | -18 | -16 | -81 | -158 | -896 | -326 | -677 | -508 |
| Cash from Financing Activity + | -21 | 136 | -132 | 233 | 333 | -66 | 288 | -83 |
| Net Cash Flow | 25 | 143 | -40 | 373 | -433 | 115 | 52 | 60 |
| CFO/OP | 196 | 34 | 96 | 128 | 60 | 125 | 110 | 129 |
| Free Cash Flow | 48 | 16 | 151 | 272 | 111 | 497 | 412 | 606 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Public | 92.38% | 92.01% | 91.01% | 89.8% | 82.75% | 81.74% | 80.44% | 81.43% | 81.34% |
| FII | 3.79% | 4.82% | 5.03% | 5.24% | 10.04% | 11.3% | 11.48% | 10.27% | 9.92% |
| DII | 3.84% | 3.17% | 3.99% | 4.96% | 7.2% | 6.95% | 8.06% | 8.29% | 8.74% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Indegene Limited (this stock) | 14,319 | 34.4 | 4.57 | 14.4% |
| Rainbow Childrens Med Ltd | 13,957 | 48.7 | 8.48 | 15.9% |
| Natco Pharma Ltd. | 15,033 | 13.1 | 1.63 | 17.1% |
| Molbio Diagnostics Ltd | 15,118 | 60.6 | — | 15.6% |
| Marksans Pharma Limited | 15,269 | 29.6 | 5.05 | 15.2% |
| Syngene International Ltd | 15,287 | 51.6 | 3.16 | 7.78% |
| Corona Remedies Limited | 13,219 | 62.3 | 17.73 | 29.5% |
Which Mutual Funds Hold Indegene Limited?
Frequently Asked Questions about Indegene Limited
Indegene Limited (INDGN) closed at ₹608.95 on NSE on 25 September 2026, up 14.85 (2.5%) from the previous close.
Indegene Limited trades on the NSE (National Stock Exchange of India) under the symbol INDGN.
Indegene Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 34.4.
Indegene Limited has a dividend yield of 0.38%.
Indegene Limited's 52-week high is ₹616.0 and its 52-week low is ₹414.0.
Indegene Limited has a market capitalisation of ₹14,319 crore.
Indegene Limited has a TopFund Quality Score of 69/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Indegene Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.